BioCardia vs Creative Medical Technology
BCDA and CELZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCDA and CELZ compare
BioCardia is the larger company, worth 3.4 times as much as Creative Medical Technology ($14.0M against $4.2M).
Creative Medical Technology scores higher on the StockData Score (7 against 5 for BioCardia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCDA | CELZ |
|---|---|---|
| Size and price | ||
| Market cap | $14.0M | $4.2M |
| Share price | $0.922 | $0.630 |
| Change, 1 year | −28.6% | −80.8% |
| Change, 5 years | −97.2% | −98.2% |
| Beta (5Y) | 1.02 | 1.56 |
| Employees | 21 | – |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1384× |
| P/B | 5.2× | 0.6× (better) |
| FCF yield | −54.3% | – |
| Growth | ||
| Revenue growth (TTM) | – | −50.0% |
| Revenue growth, 5Y average | – | −48.4% |
| Profitability | ||
| Gross margin | – | 66.9% |
| Operating margin | – | −256435% |
| Net margin | – | −249160% |
| Return on equity | −1803% | −119% (better) |
| Return on invested capital | – | −3737% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.09 | 23.66 (better) |
| Altman Z-score | −51.20 | −8.55 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −86.7% (better) | −190% |
| Shareholder yield | −86.7% (better) | −190% |
| Ownership | ||
| Held by institutions | 8.8% | 5.7% |
| Held by insiders | 11.7% | 15.9% |
| Insider net buying, 12 months | $170K | – |
| Short interest, % of float | 5.5% | 1.2% |
Go deeper
- BCDA stock overview
- BCDA income statement
- BCDA valuation and score
- CELZ stock overview
- CELZ income statement
- CELZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.